[1] Srour S A,Devesa S S,Morton LM,et al.Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States [J].Br J Haematol,2016,174(3):382-396.
[2] Ajani J A,D'Amico T A,Almhanna K,et al.Gastric cancer,version 2016,nccn clinical practice guidelines in oncology[J].JNCCN,2016,14(10):456.
[3] 陈苏宁.真性红细胞增多症诊治进展[J].中国实用内科杂志,2018,38(2):22-24.
[4] 中国抗癌协会血液肿瘤专业委员会.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志,2016,37(10):837-845.
[5] 韩 雪,白贝贝,王春健,等.真性红细胞增多症和原发性血小板增多症患者发生再次血栓事件的危险因素分析[J].中华血液学杂志,2019,40(1):17-23.
[6] Yesilova A M,Yavuzer S,Yavuzer H,et al.Analysis of thrombosis and bleeding complications in patients with polycythemia vera:a turkish retrospective study [J].Int J Hematol,2016,105(1):70.
[7] 李亚茹,李德鹏,徐开林.真性红细胞增多症的临床特征及血栓栓塞并发症危险因素分析[J].临床血液学杂志,2018,225(3):30-35.
[8] Cerquozzi S,Barraco D,Lasho T,et al.Risk factors for arterial versus venous thrombosis in polycythemia vera:a single center experience in 587 patients [J].Blood Cancer J,2017,7(12):662.
[9] Barbui T,Tefferi A,Vannucchi A M,et al.Philadelphia chromosome-negative classical myeloproliferative neoplasms:revised management recommendations from European Leukemia Net[J].Leukemia,2018,32(5):1057-1069.
[10] Borowczyk M,Wojtaszewska M,Lewandowski K,et al.The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms [J].Thromb Res,2015,135 (2):272-280.
[11] Griesshammer M,Kiladjian J J,Besses C.Thromboembolic events in polycythemia vera[J].Ann Hematol,2019,98(5):1071-1082.
[12] 俞 泓,张 蛟,贾小伟,等.血栓抽吸对急性STEMI患者PCI术后组织突出的影响[J].武警医学,2018,29(6):611-614.
[13] 蔡 伟,张 梅,姜铁民.真性红细胞增多症反复冠脉血栓 1 例[J].介入放射学杂志,2015,24(7):650-651.
[14] Parasuraman S,Yu J,Paranagama D,et al.Hematocrit levels and thrombotic events in patients with polycythemia vera:an analysis of Veterans Health Administration data [J].Ann Hematol,2019,98(11):2533-2539.